Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Citrullinated histone H4 is a post-translationally modified form of histone H4 where specific arginine residues, notably Arg3, are converted to citrulline by peptidylarginine deiminase (PAD) enzymes. This modification alters chromatin structure and gene expression, particularly during neutrophil extracellular trap (NET) formation. It acts as a regulatory "brake" on excessive NET release and is implicated in inflammatory diseases. It is a potential therapeutic target for modulating inflammation.
Currently, no drugs directly target citrullinated histone H4. Research focuses on modulating PAD enzymes to indirectly affect citrullination levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Citrullinated Histone H4 (H4Cit).